Hims & Hers Health (NYSE:HIMS) Shares Gap Down to $13.22

Hims & Hers Health, Inc. (NYSE:HIMS)’s share price gapped down before the market opened on Tuesday . The stock had previously closed at $13.22, but opened at $12.53. Hims & Hers Health shares last traded at $12.66, with a volume of 1,773,677 shares.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Citigroup upped their target price on shares of Hims & Hers Health from $12.00 to $16.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Guggenheim upped their target price on shares of Hims & Hers Health from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. SVB Leerink assumed coverage on shares of Hims & Hers Health in a report on Monday, February 26th. They set a “market perform” rating and a $10.00 target price on the stock. Imperial Capital raised shares of Hims & Hers Health from an “in-line” rating to an “outperform” rating and set a $16.00 target price on the stock in a report on Wednesday, February 28th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $15.00 target price (down previously from $17.00) on shares of Hims & Hers Health in a report on Tuesday. Five research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.85.

Hims & Hers Health Stock Down 2.4 %

The stock’s fifty day moving average price is $13.42 and its 200 day moving average price is $9.78.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, February 26th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.03. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The company had revenue of $246.60 million during the quarter, compared to analysts’ expectations of $245.84 million. During the same quarter in the prior year, the company earned ($0.05) EPS. The firm’s revenue was up 47.4% on a year-over-year basis. On average, equities research analysts expect that Hims & Hers Health, Inc. will post 0.1 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Soleil Boughton sold 2,503 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $15.65, for a total value of $39,171.95. Following the completion of the sale, the insider now owns 166,866 shares of the company’s stock, valued at approximately $2,611,452.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Hims & Hers Health news, insider Soleil Boughton sold 2,503 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $15.65, for a total transaction of $39,171.95. Following the completion of the sale, the insider now owns 166,866 shares of the company’s stock, valued at approximately $2,611,452.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Oluyemi Okupe sold 31,363 shares of the stock in a transaction on Monday, February 12th. The shares were sold at an average price of $10.03, for a total transaction of $314,570.89. Following the sale, the chief financial officer now directly owns 156,721 shares of the company’s stock, valued at approximately $1,571,911.63. The disclosure for this sale can be found here. In the last 90 days, insiders sold 675,838 shares of company stock valued at $8,487,125. Corporate insiders own 31.63% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

Several institutional investors have recently added to or reduced their stakes in HIMS. CM Wealth Advisors LLC purchased a new stake in Hims & Hers Health during the 2nd quarter valued at $25,000. Point72 Middle East FZE purchased a new stake in shares of Hims & Hers Health in the 4th quarter worth about $29,000. Captrust Financial Advisors lifted its position in shares of Hims & Hers Health by 1,827.4% in the 1st quarter. Captrust Financial Advisors now owns 6,765 shares of the company’s stock worth $36,000 after purchasing an additional 6,414 shares during the period. Harbour Investments Inc. lifted its position in shares of Hims & Hers Health by 427.9% in the 3rd quarter. Harbour Investments Inc. now owns 6,995 shares of the company’s stock worth $44,000 after purchasing an additional 5,670 shares during the period. Finally, Belpointe Asset Management LLC purchased a new stake in shares of Hims & Hers Health in the 1st quarter worth about $46,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.